Clinical trial · Observational
INTERogating Cancer for Etiology, Prevention and Therapy Navigation
INTERogating Cancer for Etiology, Prevention and Therapy Navigation (INTERCEPTioN)
NCT06008392CI-TRIAL-00107467INTERCEPTioNrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to identify markers and causes of cancer by analyzing patient's DNA (i.e., genetic material), RNA, plasma, tissues, or other samples that could be informative for patients with cancer. Cancer genetic testing is a series of tests that finds specific changes in cancer cells and normal cells in the body. Researchers may request to access these data as they explore how to better prevent, screen, or treat cancer. This study is also being done to create a biobank (library) of samples and information to learn more about treating cancer. Discovery of genetic variants in patients with cancer could result in opportunities for cancer prevention, earlier diagnosis or better therapy for cancer.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Cancer Gene Mutation | — | UNRESOLVED | — |
| Hematopoietic and Lymphoid System Neoplasm | Hematopoietic and Lymphatic System Neoplasm | ALIAS | 0.90 |
| Malignant Solid Neoplasm | Malignant Solid Neoplasm | ONTOLOGY_EXACT | 0.98 |
| PAN Gene Mutation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pan-genomic Testing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group A: Germline and Somatic Testing
- description
- Potential participants with a cancer diagnosis may be identified through the following sources: patients who will undergo or are currently undergoing clinical evaluation in practices such as, but not limited to, hematology-oncology, gastroenterology-hepatology, radiation-oncology and surgery. Participants will be enrolled in the study indefinitely unless a request to withdraw is made.
- interventionNames
- Genetic: Pan-genomic Testing
- label
- Group B: Germline Testing Only
- description
- Potential participants with a cancer diagnosis may be identified through the following sources: patients who will undergo or are currently undergoing clinical evaluation in practices such as, but not limited to, hematology-oncology, gastroenterology-hepatology, radiation-oncology and surgery. Participants will be enrolled in the study indefinitely unless a request to withdraw is made.
- interventionNames
- Genetic: Pan-genomic Testing
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: GROUP A: Germline and Somatic Testing * Has Mayo Clinic medical record number * Confirmed cancer diagnosis * Germline and/or somatic tumor/blood testing has been ordered by the clinical provider (or clinical delegate) * Participant aware of cancer diagnosis * Able to provide informed consent * ≥ 18 years old * Ability to provide blood, saliva, bone marrow aspirate or hair follicle sample * Ability to provide archived tissue, if somatic testing has not already been completed * Note: if tissue unavailable participant may still enroll onto the study for the germline collection, or vice versa, if germline has already been completed may still enroll for somatic tissue/blood testing. GROUP B: Germline testing only: * Has Mayo Clinic medical record number * Confirmed cancer diagnosis * Germline testing has been ordered by the clinical provider (or clinical delegate) * Participant aware of cancer diagnosis * Able to provide informed consent * ≥ 18 years old * Ability to provide blood, saliva, or hair follicle sample GROUP C: Somatic tumor testing only: * Has Mayo Clinic medical record number, * Confirmed cancer diagnosis, * Somatic tumor/blood testing has been ordered by the clinical provider (or clinical delegate) * Participant aware of cancer diagnosis, * Able to provide informed consent, * ≥ 18 years old * Ability to provide archived tissue or blood for somatic tumor genomic profiling, if not already completed. Group D: Clinical standard of care germline testing via genetic counselor: * Has Mayo Clinic medical record number, * Standard of care clinical visit with genetic counselor * Confirmed cancer diagnosis, * Germline testing has been ordered by the clinical provider (or clinical delegate) * Participant aware of cancer diagnosis, * Able to provide informed consent, * ≥ 18 years old * Ability to provide blood, saliva, or hair follicle sample Group E: Previous Enrollment in IRB #24-005734, 24-000609, 25-000815, 23-001689, or 24-004810: * Enrolled in any of the following studies: IRB #24-005734, 24-000609, 25-000815, 23-001689, or 24-004810 * Completed Riskguard, OncoExtra, Caris Assure, or Caris MI Profile or any combination of these tests. * Has Mayo Clinic medical record number, * Confirmed cancer diagnosis, * Participant aware of cancer diagnosis * Able to provide informed consent, * ≥ 18 years old Exclusion Criteria: Note: Women who are pregnant or planning to become pregnant can take part in this study. GROUP A: Germline and Somatic testing * Individuals who have situations that would limit compliance with the study requirements * Institutionalized (i.e. Federal Medical Prison) GROUP B: Germline testing only * Individuals who have situations that would limit compliance with the study requirements * Institutionalized (i.e. Federal Medical Prison) * Prior germline genetic testing with a 100+ multi-gene panel within the last 1 year of enrollment Group C: Somatic tumor testing only: * Individuals who have situations that would limit compliance with the study requirements, * Institutionalized (i.e. Federal Medical Prison), Group D: Clinical standard of care germline testing via genetic counselor: * Individuals who have situations that would limit compliance with the study requirements, * Institutionalized (i.e. Federal Medical Prison) Group E: Previous Enrollment in IRB #24-005734, 24-000609, 25-000815, 23-001689, or 24-004810: * Individuals who have situations that would limit compliance with the study requirements, * Institutionalized (i.e. Federal Medical Prison)
References
Publications (0)
Data not yet available
No reference posted for this study.